Streetbeat News

Analyst Ratings

SLN

Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:39 pm

RF

Morgan Stanley analyst Betsy Graseck reiterated an Overweight rating on Regions Finl (NYSE:RF) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:38 pm

PNC

Morgan Stanley analyst Betsy Graseck reiterated an Underweight rating on PNC Financial Services Group (NYSE:PNC) and maintained a $137 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:36 pm

PHVS

Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris (NASDAQ:PHVS) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:32 pm

KSCP

Ascendiant Capital Markets has initiated coverage on Knightscope, Inc. (NASDAQ:KSCP) with a buy rating and a price target of $3.50 per share. Ascendiant has a positive outlook on Knightscope's growth prospects and sees substantial upside potential for the company's stock.

Portfolio Pulse from Happy Mohamed

June 26, 2023 | 1:31 pm

MYTE

Morgan Stanley analyst Kimberly Greenberger has reiterated an Equal-Weight rating on MYT Netherlands Parent (NYSE:MYTE) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:31 pm

LUMN

Morgan Stanley analyst Simon Flannery has reiterated an Underweight rating on Lumen Technologies (NYSE:LUMN) and maintained a $2.5 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:30 pm

KARO

Morgan Stanley analyst Roy Campbell reiterated an Overweight rating on Karooooo (NASDAQ:KARO) and maintained a $37 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:29 pm

INVH

Morgan Stanley analyst Adam Kramer maintains an Overweight rating on Invitation Homes (NYSE:INVH) and raises the price target from $35 to $36.5.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:28 pm

IMCR

Morgan Stanley analyst Andrew Galler reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR) and maintained a $79 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:27 pm